drugset / Trial / NCT04673149
GLS-5310 Vaccine for the Prevention of SARS-CoV-2 (COVID-19)
RandomizedParallel-groupTriple-blindPrevention
Summary
This clinical trial will evaluate the safety, tolerability and immunogenicity of GLS-5310 DNA vaccine against SARS-CoV-2(COVID-19) in healthy volunteers.
Timeline
- Start
- 2020-12-31
- Primary completion
- 2021-03-03
- Completion
- 2023-05-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GLS-5310 | Vaccine | 0.6 mg | Other |
| Subject | GLS-5310 | Vaccine | 1.2 mg | Other |